Genfit among the biggest gainers of the SBF 120, up 31% over one month
The Lille-based biotech specializing in liver and metabolic diseases is recovering mid-session in a well-oriented Parisian market. The move follows a mixed quarterly publication and a scientific congress held this weekend in the United States.
A rebound that puts the stock back above its three moving averages
The Genfit stock gains 2.83% to €10.90, placing it among the biggest gainers of the SBF 120, which is up 0.37% at the same time.
The stock trades above its MA20 (€9.75, a gap of +11.79%), its MA50 (€10.52) and its MA200 (€10.13). This rebound largely erases the decline of the last session of last week, following the third-quarter results, while the stock still shows +30.85% over one month.
The €11.46 resistance remains the next level in the stock's sights, about 5% above the current price.
Nangibotide in ACLF: detailed review presented in Denver, data expected in 2027
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 8, at the AASLD The Liver Meeting congress in Denver, Genfit presented a detailed review of Nangibotide, its lead drug candidate for acute decompensation on cirrhosis. The efficacy signals highlighted come from studies conducted in other conditions, septic shock and severe COVID-19, and the first phase 2a data in ACLF are expected in 2027.
At the publication on November 5, the company also indicated that its resources allow it to finance its activities beyond the end of 2028, and that royalties received on sales of Iqirvo by Ipsen rose 188% over nine months. Analyst opinions on the stock remain available to put this trajectory into perspective.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
